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Abstract: When provided concurrently with soy protein for 1–3 months, soy isoﬂ  avones exert 
synergistic or additive cholesterol-lowering effects. This meta-analysis was performed to evaluate 
the effects of extracted soy isoﬂ  avones alone (not ingested concurrently with soy protein) 
on total and low density lipoprotein (LDL) cholesterol. MEDLINE (1966–2007), EMBASE 
(1966–2007), CENTRAL (1966–2007), ICHUSHI (1983–2008), and CNKI (1979–2007) were 
searched for randomized placebo-controlled trials published in English, Japanese, and Chinese, 
describing the changes in lipid proﬁ  les in adult humans resulting from ingestion of extracted soy 
isoﬂ  avones for 1–3 months. Reference lists of relevant systematic reviews and meta-analyses 
were hand-searched. Meta-analysis of 10 and 9 trials with usable information using REVMAN 
found that an average of 70 mg soy isoﬂ  avones/day (27–132 mg, as the aglycone form) alone 
had a nonsigniﬁ  cant effect on total (0.01 mmol/L [95% CI: –0.12, 0.14]; P = 0.86) and LDL 
(0.03 mmol/L [95% CI: –0.11, 0.16]; P =  0.71) cholesterol in menopausal women, respectively. 
It is concluded that ingestion of about 70 mg extracted soy isoﬂ  avones/day alone for 1–3 months 
does not improve total and LDL cholesterol levels in normocholesterolemic menopausal women; 
further studies are needed to verify the effects of extracted soy isoﬂ  avones.
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Introduction
Meta-analysis of 23 randomized controlled trials (RCTs) with durations of 3–26 weeks 
has found that soy protein ingested with isoﬂ  avones intact signiﬁ  cantly decreased 
serum levels of total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C); 
subgroup analyses demonstrated that studies employing intakes of 80 mg isoﬂ  a-
vones/day showed better effects, and that the lowering effects were most marked within 
3–12 weeks (Zhan and Ho 2005). Our previous meta-analysis of 11 RCTs found that 
ingestion of soy protein with a high isoﬂ  avone content reduced serum LDL-C to a 
greater degree than ingestion of the same amount of soy protein with a low isoﬂ  avone 
content for 1–3 months (Taku et al 2007). These two meta-analyses suggested that soy 
isoﬂ  avones would have synergistic or additive effects on cholesterol lowering when pro-
vided concurrently with soy protein for 1–3 months. However, the effects of extracted 
soy isoﬂ  avones alone (not ingested concurrently with soy protein) are unclear.
Meta-analysis of RCTs employing isoﬂ  avones in tablet form demonstrated non-
signiﬁ  cant effects on TC and LDL-C; however, only 5 of the 10 studies evaluated 
soy-derived isoﬂ  avones (Yeung and Yu 2003). So far, only one meta-analysis of 
RCTs has evaluated the effects on lipid of soy isoﬂ  avones without soy protein. This 
included 9 trials lasting 4–26 weeks, and revealed a nonsigniﬁ  cant effect of extracted 
soy isoﬂ  avones on LDL-C, although there was a high degree of heterogeneity in mean 
net changes across the studies (Balk et al 2005).Therapeutics and Clinical Risk Management 2008:4(5) 1098
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We have identiﬁ  ed several other recently published RCTs 
of soy-derived isoﬂ  avones, and the present meta-analysis was 
performed to clarify the effects of extracted soy isoﬂ  avones 
ingested alone for 1–3 months on TC and LDL-C, indepen-
dent of any effect of soy protein on the same parameters.
Subjects and methods
Study identiﬁ  cation and selection
MEDLINE (1966–2007), EMBASE (1966–2007), CEN-
TRAL (1966–2007), ICHUSHI (1983–2008), and CNKI 
(1979–2007) were searched for randomized placebo-
controlled trials published in English, Japanese, or Chinese 
describing the effects of ingesting extracted soy isoﬂ  avones 
for 1–3 months in adult humans. Reference lists of relevant 
systematic reviews (Balk et al 2005; Cassidy et al 2006; 
Sacks et al 2006), and meta-analyses (Yeung and Yu 2003; 
Zhan and Ho 2006) were hand-searched.
After excluding two RCTs (Tormala et al 2006; Badeau 
et al 2007) that were subset analyses of an original trial 
(Nikander et al 2004) and two (Lissin et al 2004; Petri Nahas 
et al 2004) in which actual endpoint TC and LDL-C values 
were not clear, 12 RCTs (Nestel et al 1997; Simons et al 
2000; Dewell et al 2002; Uesugi et al 2002, 2003, 2004; 
Nikander et al 2004; Yildiz et al 2005; Garrido et al 2006; 
Hall et al 2006; Cheng et al 2007; Gonzalez et al 2007) and 
10 RCTs (Nestel et al 1997; Simons et al 2000; Uesugi et al 
2002, 2004; Nikander et al 2004; Yildiz et al 2005; Garrido 
et al 2006; Hall et al 2006; Cheng et al 2007; Gonzalez et al 
2007) that had respectively evaluated the effects of ingesting 
extracted soy isoﬂ  avones alone on TC and LDL-C in adult 
humans for 1–3 months, and had reported actual endpoint 
values for each of the comparison groups, were included in 
the meta-analysis. Two trials (Yildiz et al 2005; Garrido et al 
2006) and one trial (Garrido et al 2006) were subsequently 
withdrawn, leaving 10 and 9 RCTs with usable information 
that were ﬁ  nally selected for meta-analysis of TC and LDL-C, 
respectively (see Figure 1). Two reviewers independently 
reviewed and evaluated the studies, and consensus was 
reached by discussion when there were disagreements.
Data extraction
Data on study design and duration, subjects, total soy iso-
ﬂ  avones, baseline TC and LDL-C for the isoﬂ  avone group, 
the numbers of participants (N) in each of the comparison 
groups, and the means and SDs of the endpoint TC and 
LDL-C values were independently extracted for meta-
analysis by two reviewers with double-checking. Normally, 
serum cholesterol and TG concentrations are about 3% higher 
Potentially relevant RCTs 
identified and screened for 
retrieval (n = 1903)
RCTs excluded because not 
relevant to topic (n = 1550)
RCTs retrieved for more 
detailed evaluation (n = 353)
RCTs excluded because of not 
reporting effects of extracted 
soy isoflavones on TC and  
LDL-C compared with placebo 
within 1–3 mo (n = 337)
Potentially appropriate RCTs to  
be included in the meta-
analysis (n = 16)
RCTs excluded from meta-
analysis because of being 
subset analyses of an original 
trial and precise data being 
unavailable (n = 4)
RCTs included in the meta-
analysis
(TC, n = 12; LDL-C, n = 10)
RCTs withdrawn, by outcome, 
because of introducing 
significant heterogeneity
(TC, n = 2; LDL-C, n = 1)
RCTs with usable information, 
by outcome
(TC, n = 10; LDL-C, n = 9)
Figure 1 The QUOROM statement ﬂ  ow diagram.
Notes: Potentially relevant randomized controlled trials (RCTs) were identiﬁ  ed from 
database PubMed (n = 837), CENTRAL (n = 386), EMBASE (382), ICHUSHI (n = 62) 
and CNKI (n = 236).
Abbreviations: QUOROM, quality of reports of meta-analyses of randomized 
controlled trials; RCTs, randomized controlled trials; TC, total cholesterol; LDL-C, 
low density lipoprotein cholesterol.
than corresponding plasma concentrations (LMC 1977), but 
because we were interested in mean differences in each study, 
we analyzed plasma and serum concentrations without cor-
rection for this difference; all results are reported as blood 
concentrations here.
Assessment of study quality
Sensitivity analyses on the basis of methodological quality dem-
onstrated that poor-quality studies indicated a positive effect Therapeutics and Clinical Risk Management 2008:4(5) 1099
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of treatment, whereas no beneﬁ  t was observed in high-quality 
studies (Khan et al 1996). We used the Jadad scale (Jadad 
et al 1996) to assess the quality of RCTs included in the meta-
analysis. The Jadad scale assesses randomization, blinding, 
and reporting of withdrawal and dropouts, and assigns studies 
quality scores ranging from 0 to 5, with a score of 2 indicat-
ing high quality (Lind et al 2001; Sjogren and Halling 2002). 
Concealment of treatment allocation in RCTs was assessed as 
adequate, inadequate, or unclear (Schulz et al 1995).
Meta-analysis
We performed the meta-analysis to determine the combined 
effect of extracted soy isoﬂ  avones alone on TC and LDL-C 
using the weighted mean difference method in REVMAN 
(version 4.2.10; Cochrane Collaboration, Oxford, UK), by 
inputting the N and the means and SDs of endpoint lipid 
concentrations for two groups in each comparison. The 
treatment effect was estimated as the mean difference in 
endpoint values between comparison groups (ie, the value 
for subjects ingesting extracted soy isoﬂ  avones alone minus 
that for subjects ingesting a placebo). We did not use mean 
change from baseline outcomes instead of mean endpoint 
value outcomes, because mean changes were not available 
in most of the included studies, and imputed SDs of the 
changes should not be used for a majority of studies in a 
meta-analysis (Cochrane 2006). Although 2 of the 12 RCTs 
reported both endpoint values and changes (Nikander et al 
2004) or percentage changes (Gonzalez et al 2007) from 
the baseline, we used endpoint value outcomes to maintain 
consistency across trials.
We used either a ﬁ  xed effect model or a random effects 
model to calculate weighted mean differences (WMD), 95% 
CIs for each comparison, a combined overall effect with 
P-value, and the P-value for testing heterogeneity (P  0.1 
was considered signiﬁ  cant). We presented the results based 
on the random effects model when there was heterogeneity 
that could not be readily explained (Zhan and Ho 2005; 
Cochrane 2006); otherwise, the results obtained using the 
ﬁ  xed effect model were presented.
To explore the possible reasons for differences in results 
across trials, especially when the test for heterogeneity was 
signiﬁ  cant (P  0.1 or I  2  25%) (Cochrane 2006; Nelson 
et al 2006), we performed subgroup meta-analyses based 
on variability in the participants’ baseline TC and LDL-C, 
intervention duration, dose of soy isoﬂ  avones, study design 
and study quality (Yeung and Yu 2003; Zhan and Ho 2005). 
Sensitivity analyses were performed on the basis of par-
ticipants’ baseline TC and LDL-C, dose of soy isoﬂ  avones, 
and study quality. We examined potential publication bias 
by using funnel plots of the SEs of the studies against their 
corresponding effect sizes.
Results
Study and treatment group 
characteristics
The characteristics of the 12 RCTs included in the meta-
analysis are summarized in Table 1. Six trials used a parallel 
design, and the remaining trials used a crossover design. Con-
cealment of treatment allocation for all trials was assessed as 
“unclear” due to insufﬁ  cient information. All trials focused 
on menopausal women. Doses of total soy isoﬂ  avones were 
42–150 mg/day (27–132 mg/day expressed as the aglycone 
form). One trial (Yildiz et al 2005) reported extremely small 
SDs for endpoint TC values, compared with SDs for other 
lipids in the trial and SDs reported in remaining trials. Sig-
niﬁ  cantly different endpoint TC and LDL-C values between 
the two comparison groups were reported in two trials (Yildiz 
et al 2005; Garrido et al 2006) and one trial (Garrido et al 
2006), respectively, possibly due to their signiﬁ  cantly dif-
ferent baseline values; the remaining trials did not reported 
signiﬁ  cantly different TC and LDL-C values at the baseline 
and endpoint between comparison groups.
In addition, subjects in most of the comparisons had 
similar diets, with similar amounts of fat (total and saturated), 
cholesterol, and ﬁ  ber. Most of the studies were designed to 
maintain subjects’ usual diets and lifestyles. No signiﬁ  cant 
differences in age, body weight, or body mass index were 
reported between the comparison groups.
Adverse events of extracted soy isoﬂ  avones were evalu-
ated according to the evidence report (Balk et al 2005). Of 
the 12 RCTs included, one trial (Garrido et al 2006) that used 
100 mg soy isoﬂ  avones/day reported one case of abdominal 
bloating and one case of nicturia; one trial (Nikander et al 
2004) using 114 mg soy isoﬂ  avones/day reported two cases 
of gastralgia and one recurrence of breast cancer; one trial 
(Simons et al 2000) using 80 mg soy isoﬂ  avones/day reported 
one case of paresthesia and one case of brief menstrual 
period 5 weeks into the treatment (the subject being 2 
years postmenopausal).
Meta-analysis
Meta-analysis of the 12 RCTs that reported the endpoint TC 
demonstrated signiﬁ  cant heterogeneity (P  0.00001). Use 
of the random effects model did not reveal any signiﬁ  cant 
effect of extracted soy isoﬂ  avones alone on TC. Excluding 
two outlying trials (Yildiz et al 2005; Garrido et al 2006) Therapeutics and Clinical Risk Management 2008:4(5) 1100
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showing the poorest overlap (apparently due to the extremely 
small SDs and signiﬁ  cant difference in baseline values) on the 
forest plot, meta-analysis of 10 RCTs with usable informa-
tion (see Figure 1) using the ﬁ  xed effect model demonstrated 
nonsigniﬁ  cant heterogeneity and a nonsigniﬁ  cant effect of 
an average intake of 73 (27–132, as the aglycone form) mg 
soy isoﬂ  avones/day on TC (0.01 mmol/L [95% CI: –0.12, 
0.14]; P = 0.86). Results obtained using the random effects 
model were identical.
Meta-analysis of the 10 RCTs that reported the endpoint 
LDL-C demonstrated signiﬁ  cant heterogeneity (P = 0.003), 
and use of the random effects model revealed no signiﬁ  -
cant effect of extracted soy isoﬂ  avones alone on LDL-C. 
Excluding one outlying trial (Garrido et al 2006) with the 
poorest overlap (apparently due to the signiﬁ  cant differ-
ence in baseline values) on the forest plot, meta-analysis 
of 9 RCTs with usable information (see Figure 1) demon-
strated nonsigniﬁ  cant heterogeneity and a nonsigniﬁ  cant 
effect of an average intake of 67 (27–132, as the aglycone 
form) mg soy isoﬂ  avones/day using the ﬁ  xed effect model 
(see Figure 2) on LDL-C (0.03 mmol/L [95% CI: –0.11, 
0.16]; P = 0.71). Results obtained using the random effects 
model were similar.
Subgroup analyses for the effect on LDL-C found that 
trials lasting 2 months resulted in signiﬁ  cant heterogeneity 
and that trials with a parallel design resulted in a signiﬁ  cant 
effect (see Table 2). Subgroup analyses for the effect on 
TC on the basis of the same variables did not reveal any 
subgroups with significant results. Sensitivity analyses 
excluding one trial with LDL-C  3.36 mmol/L (Cheng 
et al 2007) or one trial with TC  6.21 mmol/L (Dewell et al 
202), trials that evaluated 20–40 (or  80) mg soy isoﬂ  avone 
aglycones/day, or trials of poor quality did not signiﬁ  cantly 
inﬂ  uence the results. The funnel plots for the effects on TC 
and LDL-C did not indicate any obvious publication bias 
(data not shown).
Table 1 Characteristics of 10 included randomized placebo-controlled trials with usable information
Study and 
reference
Design and 
durationa
Subjectsb Total soy isoﬂ  avones 
(mg/d)c
Jadad 
scale
Baseline lipidsd
TC LDL-C
Cheng et al 2007 P; R+; DB+; WD 
(15%); 3 mo
60 healthy PoW 60 [37 (De, 41%; Ge, 52%; 
Gle, 7%)]
5 5.70 3.10
Dewell et al 2002 P; R; DB; WD 
(0%); 2 mo
36 PoW 150 (Ge, 27%; De and Gle, 33%; 
glycosides, 40%) [128]
3 6.80 NR
Garrido et al 2006 P; R; DB+; 12 wk 29 healthy PoW [95 (De, 49%; Ge, 51%)] 3 5.50* 3.40*
Gonzalez et al 
2007
CO; R+; DB+; 
WD (19%); 12 wk
32 type 2 diabetes PoW [132 (De, 37%; Ge, 53%; 
Gle, 10%)]
5 5.40 3.40
Hall et al 2006 CO; R; DB+; WD 
(12%); 8 wk
117 healthy PoW [50 (De, 33%; Ge, 67%)] 4 6.03 3.88
Nestel et al 1997 CO; R; SB; WD 
(9%); 5 wk
23 MPW [80 (De, 42%; Ge, 54%; 
Gle, 4%)]
2 5.54 3.57
Nikander et al 2004  CO; R+; DB+; 
WD (10%); 3 mo
62 PoW with a history 
of breast cancer
[114 (De, 36%; Ge, 6%; 
Gle, 58%)]
5 5.88 3.87
Simons et al 2000 CO; R; DB+; WD 
(13%); 8 wk
23 healthy PoW [80 (De and Ge, 100%)] 4 5.86 3.94
Uesugi et al 2002 P; R; DB; WD 
(0%); 4 wk
23 healthy PW 62 [38 (De, 52%; Ge, 11%; 
Gle, 37%)]
3 5.85 3.83
Uesugi et al 2003 P; R; WD (4%); 
3 mo
22 PoW 62 [38 (De, 52%; Ge, 11%; 
Gle, 37%)]
2 5.79 NR
Uesugi et al 2004 CO; R; DB+; 4 wk 58 CW 42 [27 (De, 46%; Ge, 13%; 
Gle, 41%)]
3 5.87 3.62
Yildiz et al 2005 P; R; SB; WD (0%); 
3 mo
80 healthy PoW [40 mg/d (Ge, 100%)] 2 5.81* 3.98
Notes: aP, Parallel; CO, crossover; R, randomized; R+, randomized by appropriate method; DB, double-blinded; DB+, double-blinded by appropriate method; SB, single-blinded; 
WD, withdrawals and dropouts described. bNumber randomized; PoW, postmenopausal women; MPW, menopausal and perimenopausal women; PW, perimenopausal women; 
CW, climacteric women. cValues in brackets are expressed as the aglycone form; De, daidzein; Ge, genistein; Gle, glycitein. d Total cholesterol (TC ) and LDL cholesterol (LDL-C) 
concentration (mmol/L) for soy isoﬂ  avones treatment group; to convert mg/dL to mmol/L, multiply by 0.02586; *P < 0.05 vs. placebo.Therapeutics and Clinical Risk Management 2008:4(5) 1101
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Discussion
Although two previous meta-analyses have suggested that 
soy isoﬂ  avones have synergistic or additive effects in low-
ering TC and LDL-C when provided concurrently with soy 
protein for 1–3 months, especially in hypercholesterolemic 
(TC  6.21 mmol/L or LDL-C  4.14 mmol/L) subjects 
(Zhan and Ho 2005; Taku et al 2007), the present meta-
analysis found that ingestion of an average of 70 mg 
extracted soy isoﬂ  avones/day (as the aglycone form) alone 
(not ingested concurrently with soy protein) for 1–3 months 
did not signiﬁ  cantly change TC and LDL-C compared with 
placebo in normocholesterolemic menopausal women. The 
Table 2 Combined treatment effect of extracted soy isoﬂ  avones alone on LDL cholesterol in subgroup analyses
Variables No. of 
trials
Sample size 
(ESI/PLA)
WMD (95% CI) 
(mmol/L)
P for effect P for 
heterogeneity
Baseline LDL cholesterol
3.36 mmol/L 1 26/21 −0.04 (−0.86, 0.06) 0.09 Not available
3.36 mmol/L 8 330/328 0.07 (−0.08, 0.21) 0.35 0.47
Study duration
2 mo 5 228/226 0.06 (−0.11, 0.24) 0.49 0.87
2 mo 4 128/123 −0.07 (−0.46, 0.31) 0.70 0.04
Total isoﬂ  avone aglycones
20–40 mg/d 4 116/110 −0.11 (−0.35, 0.13) 0.35 0.11
41–80 mg/d 3 158/157 0.02 (−0.19, 0.23) 0.83 0.91
80 mg/d 2 82/82 0.24 (−0.05, 0.54) 0.10 0.43
Daidzein and genistein
20–40 mg/d 4 116/110 −0.11 (−0.35 0.13) 0.35 0.11
41–80 mg/d 4 214/213 0.10 (−0.09, 0.28) 0.30 0.52
80 mg/d 1 26/26 0.10 (−0.36, 0.56) 0.67 Not available
Study design
Parallel 3 58/52 −0.42 (−0.75, 0.08) 0.02 0.97
Crossover 6 298/297 0.11 (−0.04, 0.27) 0.14 0.79
Study quality
High 7 315/308 0.06 (−0.10, 0.21) 0.47 0.30
Poor 2 41/41 −0.09 (−0.39, 0.21) 0.57 0.12
Abbreviations: WMD, weighted mean difference; ESI, extracted soy isoﬂ  avones; PLA, placebo.
Figure 2 Effect of extracted soy isoﬂ  avones (ESI) alone on blood LDL cholesterol.
Notes: Weight assigned by REVMAN software based on N and SD. WMD, Weighted mean difference in endpoint values between the ESI alone (not ingested concurrently with 
soy protein) and placebo groups; ﬁ  xed, ﬁ  xed effect model. Horizontal lines denote the 95% CI. , point estimate (size of the square corresponds to its weight); , combined 
overall effect of ESI treatment.
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inconsistency of the results might be due mainly to the 
differences in effects between extracted soy isoﬂ  avones alone 
and soy isoﬂ  avones provided concurrently with soy protein. 
Another explanation might be that the two previous meta-
analyses included more trials evaluating the effects of soy 
protein using larger amounts of soy-associated isoﬂ  avones in 
hypercholesterolemic subjects and used different approaches 
to determine the combined treatment effects. The lack of any 
beneﬁ  cial effects of extracted soy isoﬂ  avones alone on TC 
and LDL-C was consistent with a previous meta-analysis 
that evaluated RCTs of soy isoﬂ  avones without soy protein 
(Balk et al 2005). However, that study noted a high degree 
of heterogeneity with mean net changes across the 9 included 
trials with durations of 4–26 weeks using the inverse variance 
method and by arbitrarily assuming the correlation coefﬁ  cient 
between baseline and endpoint lipid values to be 0.5.
A large cohort study reported that high isoﬂ  avone intake 
from soy foods was associated with a reduced risk of cerebral 
and myocardial infarction in Japanese women, the risk reduc-
tion being pronounced for postmenopausal women (Kokubo 
et al 2007). It is still unclear why intake of isoﬂ  avones as a 
component of intact soy protein or soy foods had beneﬁ  cial 
effects on lipid proﬁ  le, whereas extracted soy isoﬂ  avones 
alone had no such effects. When producing the soy isoﬂ  avone 
extract, alcohol extraction may have removed the active agent, 
the isoﬂ  avones may have been inactivated during the process 
of puriﬁ  cation, or some enabling factor in soy protein may 
be required for the beneﬁ  cial effects of soy isoﬂ  avones on 
lipid proﬁ  les (Clarkson and Anthony 1998). The beneﬁ  cial 
effects of soy protein might require synergistic interaction 
between isoﬂ  avones and other soy components (Clarkson 
2002). Isoﬂ  avone glycosides are not absorbed intact across the 
enterocytes of healthy adults, and their bioavailability requires 
initial hydrolysis by intestinal β-glucosidases for uptake to the 
peripheral circulation (Setchell et al 2002). Absorption of iso-
ﬂ  avones is affected by food matrix and processing in humans 
(de Pascual-Teresa et al 2006), and differences in bioavail-
ability between soy isoﬂ  avones contained in intact soy protein 
and in various extract supplements (without soy protein) may 
account for the differences in effects on lipid proﬁ  les.
Subgroup and sensitivity analyses based on participants’ 
baseline lipid values, soy isoﬂ  avone dose, and study quality 
revealed no signiﬁ  cant inﬂ  uence of extracted soy isoﬂ  avones 
on TC and LDL-C. However, interpretation of the results 
for any of the variables considered is limited because of the 
small number of trials available. We did not conduct sub-
group analysis to evaluate the effect of isoﬂ  avone metabolites 
(equol and O-DMA) because only one trial had reported that 
being an equol producer or nonproducer was not a factor 
inﬂ  uencing the effects of extracted soy isoﬂ  avones on lipid 
proﬁ  les (Nikander et al 2004); another trial reported the uri-
nary excretion of equol and O-DMA for equol producers and 
nonproducers, but did not address the effect on lipids.
In conclusion, our meta-analysis has shown that ingestion 
of about 70 mg extracted soy isoﬂ  avones/day (as the aglycone 
form) alone (not ingested concurrently with soy protein) for 
1–3 months does not decrease blood TC and LDL-C levels 
in normocholesterolemic menopausal women. Further studies 
are needed to verify the long-term effects of extracted soy iso-
ﬂ  avones alone in other subjects and possible adverse events.
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